Podcast

Still capturing and evaluating patient preferences does not belong to the core capabilities of most biostatisticians.

In this episode, we dig into the different aspects of this highly personal decision. Given, that Benjamin went directly into a job, whereas I first finalized my PhD, we also offer our experiences.

Oliver has accrued lots of experience working in different setups over his career and thus can tell about the different strengths and limitations of the set-ups.

Benefit-risk assessments are made by various stakeholders including sponsors, regulators, payers, physicians, and patients throughout the life-cycle of a treatment.

We’ll explore where leadership powers originate, how they shape decision-making, and most importantly, how you can harness them to amplify your influence and effectiveness within your statistical domain.

This episode follows the outline of a webinar, that I presented in 2018 during a PSI webinar. I’m introducing cluster analysis and why you as a statistician need to know about it.

Stephen Ruberg answers these and related questions in today’s episode. Coming from the medical side, he built a business analytics team at Lilly and gave a related keynote presentation at the 2018 PSI conference.

Then this interview with Ursula from Cytel provides you with the relevant answers.

In this episode, he shares the different methods he’s using. We also dive into common pitfalls, that we as statisticians trap into.

Pepa Polavieja Pepa Polavieja is a biostatistician with 22 years of experience in the pharmaceutical industry, working across early and late stages and many therapeutic areas, performing varying roles. In the last 15 years, Pepa has been working for Lilly, having different roles in the Global Statistics and Sciences organization. She was a group leader … Weiterlesen …